Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS-C: AZD9838 and AZD6563 Vaccine in Adults
NCT06147063Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2023
- Primary completion
- Apr 2024
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AZD9838 and AZD6563 in coronavirus disease 2019 (COVID-19) (8 arms), sponsored by AstraZeneca. Primary endpoints: Adverse Events at 28 days, Adverse Reactions at 7 days and 4 more. Started Nov 2023; status: completed.
02
Drugs
AZD9838AZD6563
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06147063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06147063.